Listen

Add to my selection

STIVARGA (régorafénib monohydraté)

Medicine - Posted on Oct 24 2018 - Updated on Jun 12 2019

Active substance (DCI)

régorafénib monohydraté

history (3)

1/31/18

STIVARGA (regorafenib), tyrosine kinase inhibitor

High clinical benefit in the treatment of hepatocellular carcinoma in patients in good general condition (ECOG 0-1), with pr...

CAV :
54321

icône flèche
10/7/15

STIVARGA (regorafenib), protein kinase inhibitor

Minor improvement in the third-line treatment of unresectable or metastatic gastrointestinal stromal tumours STIVARGA now ha...

CAV :
54321

icône flèche
5/14/14

STIVARGA (regorafenib), tyrosine kinase inhibitor

No clinical benefit demonstrated in the management of metastatic colorectal cancer Actual benefit low in patients with an EC...

CAV :
54321

icône flèche

Technical information

ATC code

L01XE21

Manufacturer

BAYER HEALTHCARE SAS

Presentation

STIVARGA 40 mg, comprimé pelliculé (code CIS : 69548508)
3 flacons de 28 comprimés - Code CIP : 34009 275 200 0 6

All our publications

Digestive system cancers